TargetMol

Eflucimibe

Product Code:
 
TAR-T27245L
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20°C
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T27245L-1mg1mg£227.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27245L-5mg5mg£416.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27245L-10mg10mg£581.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27245L-25mg25mg£863.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27245L-50mg50mg£1,163.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27245L-100mg100mg£1,540.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27245L-500mg500mg£3,026.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Eflucimibe is an acyl coenzyme A: cholesterol acyltransferase inhibitor for the treatment of cardiovascular disease and endocrine and metabolic disorders, and can be used to study atherosclerosis and hyperlipidemia.
CAS:
202340-45-2
Molecular Weight:
469.72
Pathway:
Metabolism
Purity:
0.9856
SMILES:
[C@H](C(NC1=C(C)C(C)=C(O)C(C)=C1)=O)(SCCCCCCCCCCCC)C2=CC=CC=C2
Target:
Acyltransferase

References

Mesplet N, et al. Spectrofluorimetric study of eflucimibe-gamma-cyclodextrin inclusion complex. Eur J Pharm Biopharm. 2005;59(3):523-526. Rodier E, et al. A three step supercritical process to improve the dissolution rate of eflucimibe. Eur J Pharm Sci. 2005;26(2):184-193.